Norwegian Cruise Line Holdings Ltd. current report, 15 November 2021

Business Context and Reporting Period

This Form 8-K filing by Norwegian Cruise Line Holdings Ltd. (NCLH) reports on events occurring on November 15, 2021, with transactions closing on November 19, 2021. The filing details a significant capital restructuring involving a private offering of exchangeable senior notes and a registered direct equity offering. The primary objective was to refinance higher-cost debt and improve the company's liquidity position amidst the ongoing impacts of the COVID-19 pandemic.

Key Financial Metrics and Transaction Details

Notes Offering

  • Instrument: $1.15 billion aggregate principal amount of 1.125% exchangeable senior notes due 2027.
  • Proceeds: Gross proceeds of $1.15 billion; net proceeds of $1.121 billion (after discounts, before expenses).
  • Interest: 1.125% per year, payable semi-annually starting February 15, 2022.
  • Exchangeability: Exchangeable into NCLH ordinary shares at an initial exchange price of approximately $33.69 per share (a 42.50% premium to the concurrent equity offering price).

Equity Offering

  • Instrument: 46,858,854 ordinary shares sold to holders of the 2024 Exchangeable Notes.
  • Price: $23.64 per share.
  • Use of Proceeds: Redeem $236.25 million of 12.25% Senior Secured Notes due 2024 and $262.50 million of 10.250% Senior Secured Notes due 2026; pay related premiums and expenses; and repurchase a portion of the 2024 Exchangeable Notes.

Debt Repurchases

  • 2024 Exchangeable Notes: Repurchased $715.9 million aggregate principal amount for approximately $1.4 billion (including accrued interest and premiums).
  • Senior Secured Notes: Planned redemption of $236.25 million (due 2024) and $262.50 million (due 2026) using equity proceeds.

Material Changes and Strategic Impact

The transactions represent a material change in NCLH's capital structure, shifting from higher-interest senior secured debt to lower-interest exchangeable notes and equity. By repurchasing $715.9 million of 6.00% exchangeable notes and redeeming portions of 12.25% and 10.250% senior secured notes, the company significantly reduced its weighted average interest rate and near-term debt maturities. The equity offering price of $23.64 per share established a market valuation baseline, while the exchangeable notes were priced with a 42.50% premium to this level, reflecting the value of the exchange option.

Guidance, Outlook, and Risks

The filing does not provide specific numerical guidance for future revenue or earnings. However, management commentary and the "Cautionary Statement Concerning Forward-Looking Statements" highlight significant risks and uncertainties:

  • COVID-19 Impact: Continued adverse effects on travel demand, operations, and liquidity due to the pandemic and CDC Conditional Order restrictions.
  • Liquidity Needs: Potential need for additional financing to optimize the balance sheet, which may be dilutive or unavailable on favorable terms.
  • Operational Risks: Risks related to port availability, fuel price volatility, shipbuilding delays, and the ability to maintain health and safety protocols.
  • Financial Covenants: Restrictions in debt agreements requiring minimum liquidity levels and limiting operational flexibility.

Investor Verification Checklist

  • Verify the exact amount of cash remaining after the $1.4 billion repurchase of 2024 Exchangeable Notes and the planned redemptions of senior secured notes.
  • Confirm the dilution impact of the 46.8 million shares issued in the Equity Offering and the potential future dilution from the exchange of the $1.15 billion Notes (up to 48.6 million shares).
  • Review the specific terms of the "make-whole" provisions and fundamental change repurchase obligations in the new Notes indenture.
  • Assess the company's current liquidity position relative to the minimum levels required by its remaining debt agreements.
  • Monitor the status of CDC restrictions and the timeline for the full resumption of cruise voyages as referenced in the risk factors.